1. Zager R.A. Rhabdomyolysis and myohemoglobinuric acute renal failure // Kidney Int. 1996. 49. (2). 314–326.
2. Baliga R., Ueda N., Walker P.D., Shah S.V. Oxidant mechanisms in toxic acute renal failure // Drug Metab. Rev. 1999. 31. 971–997.
3. Clyne D.H., Kant K.S., Pesce A.J., Pollak V.E. Nephrotoxicity of low molecular weight serum proteins: physicochemical interactions between myoglobin, hemoglobin, bence-jones proteins and tamm-horsfall mucoprotein // Curr. Probl. Clin. Biochem. 1979. (9). 299–308.
4. Flögel U., Merx M.W., Godecke A. et al. Myoglobin: A scavenger of bioactive NO // Proc. Natl. Acad. Sci. USA. 2001. 98. (2). 735–740.
5. Ayer G., Grandchamp A., Wyler T., Truniger B. Intrarenal hemodynamics in glycerol-induced myohemoglobinuric acute renal failure in the rat // Circ. Res. 1971. 29. (2). 128–135.
6. Rosenberger C., Goldfarb M., Shina A. et al. Evidence for sustained renal hypoxia and transient hypoxia adaptation in experimental rhabdomyolysis-induced acute kidney injury // Nephrol. Dial. Transplant. 2008. 23. (4). 1135–1143.
7. Tsikas D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids //Free Radic. Res. 2005. 39. (8). 797–815.
8. Гилинский М.А. Асимметричный диметиларгинин: метаболизм, аргининовый парадокс, патофизиология // Успехи физиол. наук. 2007. 38. (3). 21–39.
9. Teerlink T., Luo Z., Palm F., Wilcox C.S. Cellular ADMA: regulation and action // Pharmacol. Res. 2009. 60. (6). 448–460.
10. Böger R.H., Bode-Böger S.M. The clinical pharmacology of L-arginine // Annu. Rev. Pharmacol. Toxicol. 2001. 41. 79–99.
11. Sourcebook of models for biomedical research / Ed. P.M. Conn. Totowa: Humana Press, 2008. 786 p.
12. Navarro-Gonzálvez J.A., Garcнa-Benayas C., Arenas J. Semiautomated measurement of nitrate in biological fluids // Clin. Chem. 1998. 44. (3). 679–681.
13. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids // J. Chromatogr. B. 2007. 851. (1–2). 21–29.
14. Гилинский М.А., Айзман Р.И., Корощенко Г. А. и др. Метиларгинины у крыс в глицериновой модели острой почечной недостаточности // Бюл. СО РАМН. 2010. (4). 82–86.
15. Герасев А.Д., Луканина С.Н., Святаш Г. А., Айзман Р.И. Влияние природных цеолитов на функции почек крыс в условиях острой почечной недостаточности // Нефрология и диализ. 2000. 2. (4). 21–24.
16. Schramm L., La M., Heidbreder E. et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation // Kidney Int. 2002. 61. (4). 1423–1432.
17. Chander V., Chopra K. Molsidomine, a nitric oxide donor and L-arginine protects against rhabdomyolysis-induced myoglobinuric acute renal failure // Biochim. Biophys. Acta. 2005. 1723. (1–3). 208–214.
18. Wang Z., Tang W.H., Cho L. et al. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition // Arterioscler. Thromb. Vasc. Biol. 2009. 29. (9). 1383–1391.
19. Tojo A., Welch W.J., Bremer V. et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney // Kidney Int. 1997. 52. (6). 1593–1601.
20. Matsuguma K., Ueda S., Yamagishi S. et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease // J. Am. Soc. Nephrol. 2006. 17. (8). 2176–2183.